Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including...
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025;...
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation...
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L...
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.